Skip to main content

pharmaceutical stocks

3 articles found

Novo Nordisk Slashes Ozempic and Wegovy Prices by Up to 50%

Novo Nordisk dropped a bombshell on Tuesday, announcing it will slash the U.S. list prices of its blockbuster weight-loss and diabetes drugs — Wegovy, Ozempic, and Rybelsus — by up to 50% starting January 1, 2027. All three treatments will carry a new list price of $675 per month, down from approximately $1,350 for Wegovy and $1,027 for the diabetes drugs. The move is specifically designed to relieve the cost burden on insured patients with high-deductible health plans or coinsurance benefit structures. The announcement lands at perhaps the worst possible moment for the Danish pharmaceutical giant. Just one day earlier, shares cratered 16% after Novo's next-generation obesity drug CagriSema failed to demonstrate non-inferiority against Eli Lilly's Zepbound in the pivotal REDEFINE-4 phase III trial. The double blow has sent NVO shares tumbling to $38.58 — a new 52-week low — erasing more than half its market capitalization from last year's peak of $93.80. The stock is now down nearly 59% from its highs, and trading at its lowest P/E ratio in years at just 10.5x earnings. For investors, the twin developments crystallize a question that has been building for months: Is Novo Nordisk ceding the GLP-1 weight-loss throne to Eli Lilly, or is this a generational buying opportunity for one of pharma's most profitable franchises?

Novo NordiskOzempicWegovy

MRK Analysis: Merck's Keytruda Patent Cliff Looms

Merck & Co. (NYSE: MRK) is trading at $122.26, just pennies from its 52-week high of $123.33, capping a remarkable 67% recovery from its $73.31 low. The $305 billion pharmaceutical giant has delivered full-year 2025 revenue of approximately $65 billion on the strength of Keytruda, the world's best-selling drug with annual sales exceeding $25 billion. At a trailing P/E of 16.8x on $7.28 in earnings per share, Merck trades at a meaningful discount to the S&P 500 — but the market is pricing in a very specific risk. That risk is the Keytruda patent cliff. The blockbuster cancer immunotherapy's U.S. composition-of-matter patent expires in 2028, and biosimilar competition will follow. Keytruda alone represents roughly 40% of Merck's total revenue, making this one of the largest single-product revenue cliffs in pharmaceutical history. Management has spent aggressively on pipeline development, subcutaneous reformulations, and acquisitions to bridge the gap — but whether those efforts will be enough remains the central question for MRK shareholders. With the stock near all-time highs and analyst sentiment turning increasingly bullish — Seeking Alpha recently noted the 6.8% year-over-year increase in pembrolizumab franchise sales to $8.37 billion in Q4 — this analysis examines whether Merck's valuation adequately prices in the patent cliff or if the pipeline offers enough upside to justify buying at these levels.

Merck stock analysisMRK stockKeytruda patent cliff

LLY: Eli Lilly's $952 Billion Pharma Empire Delivers 85%

Eli Lilly and Company (NYSE: LLY) has transformed from a traditional pharmaceutical giant into the undisputed leader of the weight loss drug revolution. Trading at $1,009.52, the Indianapolis-based company commands a $952 billion market capitalization — making it the most valuable pharmaceutical company in the world. With full-year 2025 revenue of $65.2 billion and net income of $20.6 billion, Lilly's financial trajectory has been nothing short of extraordinary. The story behind Lilly's meteoric rise centers on two blockbuster GLP-1 receptor agonist drugs: Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for chronic weight management. These medications have generated unprecedented demand, propelling quarterly revenue from $12.7 billion in Q1 2025 to $19.3 billion in Q4 2025 — a 52% sequential acceleration in a single year. The stock sits 11% below its 52-week high of $1,133.95 but has surged 62% from its 52-week low of $623.78, reflecting both the massive opportunity ahead and the premium valuation investors are willing to pay. Beyond weight loss, Lilly continues to expand its pipeline across immunology, oncology, and neuroscience. Recent Phase 3 data showed Omvoh achieving over 90% steroid-free remission in Crohn's disease patients at three years — a landmark result that opens another multi-billion-dollar market. For investors, the central question is whether Lilly's growth trajectory justifies paying nearly 44 times earnings for a pharma stock.

LLY stock analysisEli Lilly stockGLP-1 drugs